Company Overview and News

 
Mack Trading Co reports standalone net profit of Rs 0.01 crore in the June 2016 quarter

2016-08-13 indiainfoline
Mack Trading Co reports standalone net profit of Rs 0.01 crore in the June 2016 quarter

 
Columbia Funds Series Trust II Form N-Q

2015-12-29 sec.gov
      OMB APPROVAL     OMB Number: 3235-0578     Expires: January 31, 2016   UNITED STATES Estimated average burden hours per response. . . . 10.5   SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549     FORM N-Q   QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY   Investment Company Act file number 811-21852   Columbia Funds Series Trust II (Exact name of registrant as specified in charter)   50606 Ameriprise Financial Center Minneapolis, MN   5547

 
COLUMBIA FUNDS SERIES TRUST Form N-Q

2015-12-29 sec.gov
      OMB APPROVAL     OMB Number: 3235-0578     Expires: January 31, 2016   UNITED STATES Estimated average burden hours per response . . . . . . . . . . 10.5   SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549     FORM N-Q   QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY   Investment Company Act file number 811-09645   Columbia Funds Series Trust (Exact name of registrant as specified in charter)   50606 Ameriprise Financial Center Minneapolis,

 
Premarket Biotech Digest: Arrowhead's Potential, KaloBios Delisting, BiondVax Patent

2015-12-28 seekingalpha
Arrowhead could take off in 2016.KaloBios will be delisted from the NASDAQ this week.Biondvax has been granted a patent for its flu vaccine.

 
Premarket Biotech Digest: Celldex's Catalyst, Shire-Baxalta Deal, PSivida Surges

2015-12-24 seekingalpha
Celldex is set up nicely for a bounce-back in 2016.Shire and Baxalta are close to completing a deal says Reuters.PSivida surges on positive data from Phase III trial.

 
Do Hedge Funds Love Merrimack Pharmaceuticals Inc (MACK)?

2015-12-13 insidermonkey
Hedge funds are not perfect. They have their bad picks just like everyone else. Micron, a stock hedge funds have loved, lost 50% during the last 12 months...

 
Do Hedge Funds Love Ollie’s Bargain Outlet Holdings Inc (OLLI)?

2015-12-13 insidermonkey
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the...

 
Hercules Technology Growth Capital Form N-2/A

2015-12-12 sec.gov
Amendment No 1. to Form N-2 Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on June 8, 2015 Securities Act File No. 333-203511     U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM N-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Check appropriate box or boxes)     Pre-Effective Amendment No. 1 Post-Effective Amendment No.

 
SEASONS SERIES TRUST Form N-CSRS

2015-12-09 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM N-CSR   CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES   Investment Company Act file number 811-07725   SEASONS SERIES TRUST (Exact name of registrant as specified in charter)   1999 Avenue of the Stars, 27th Floor, Los Angeles, CA   90067-6022 (Address of principal executive offices)   (Zip code)   John T.

 
Merrimack Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MACK) : November 30, 2015

2015-12-01 capitalcube
Click here to see latest analysisCapitalcube gives Merrimack Pharmaceuticals, Inc. a score of 38.Our analysis is based on comparing Merrimack Pharmaceuticals, Inc. with the following peers – Celgene Corporation, Sanofi Sponsored ADR, Dyax Corp., AVEO Pharmaceuticals, Inc., Geron Corporation, Clovis Oncology, Inc., Cerulean Pharma, Inc., Immunomedics, Inc., Synta Pharmaceuticals Corp. and BioTime, Inc.

 
Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : November 30, 2015

2015-12-01 capitalcube
Click here to see latest analysis*Disclaimer : This is as of previous day’s closing price.Technical IndicatorsBelow is a quick look at 5 technical indicators for Merrimack Pharmaceuticals, Inc.. More studies are available on the Technical Chart.IndicatorSignalClosing Price above/below 50 Day Moving AverageBullishClosing Price above/below 200 Day Moving AverageBearish50 Day Moving Average above/below 200 Day Moving …

 
VANGUARD VALLEY FORGE FUNDS Form N-Q

2015-12-01 sec.gov
valleyforge_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:   811-58431   Name of Registrant:   Vanguard Valley Forge Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

 
VANGUARD INSTITUTIONAL INDEX FUNDS Form N-Q

2015-12-01 sec.gov
institutionalindex_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:    811-06093   Name of Registrant:   Vanguard Institutional Index Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

 
VANGUARD INDEX FUNDS Form N-Q

2015-12-01 sec.gov
index_final.htm - Generated by SEC Publisher for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT COMPANY   Investment Company Act file number:   811-02652   Name of Registrant:   Vanguard Index Funds   Address of Registrant: P.O. Box 2600 Valley Forge, PA 19482   Name and address of agent for service: Heidi Stam, Esquire P.

 
Vanguard Montgomery Funds Form EX-99.CERT

2015-12-01 sec.gov
certifications.htm - Generated by SEC Publisher for SEC Filing   CERTIFICATIONS   I, F. William McNabb III, certify that:   1. I have reviewed this report on Form N-Q of Vanguard Montgomery Funds;   2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

MACK : Merrimack Pharmaceuticals Stock Analysis and Research Report

2017-10-23 - Asif

Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Merrimack's mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All its product candidates, including three in clinical studies and several others in preclinical development, fit into its strategy of (1) understanding the biological problems the company is trying to solve, (2) designing specific solutions and (3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes. On April 3, 2017, Merrimack Pharmaceuticals announced that the company commenced operating as a refocused research and clinical development company in connection with the completion of Merrimack's previously announced transaction, or the asset sa...

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...